Analysis of over 1.5 million people revealed that carriers of protein-disrupting variants in the CETP gene experience 27% lower atherosclerotic vascular event rates and 21% reduced coronary artery disease risk. These variants raise HDL cholesterol by 25% while lowering non-HDL cholesterol by 6%, translating to approximately one additional year of disease-free survival. This massive genetic study provides compelling evidence that lifelong CETP deficiency protects against cardiovascular disease. The findings validate decades of pharmaceutical interest in CETP inhibition as a therapeutic target, though previous drug trials yielded mixed results. The natural experiment offered by these rare variants suggests the timing and degree of CETP suppression matters crucially. For longevity science, this represents confirmatory evidence that certain genetic variants can meaningfully extend healthspan through cardiovascular protection. However, important limitations remain: the study population was predominantly of European ancestry, and carriers represent less than 0.5% of the population. As this preprint awaits peer review, the robust effect sizes across multiple large biobanks suggest these findings will likely withstand scrutiny, potentially reinvigorating therapeutic development targeting CETP pathways.